Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company reported earnings per share of €1.08 compared to Wall Street’s estimate of 44 ...

On Monday, June 2, Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating. This decision came after the company entered into an ...

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved ...

BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line." The analyst in question also hiked its price target to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...